MAP2K7 and cancer: The mitogen activated protein kinase (MAPK) signaling cascade is another pathway hyper-activated in a large number of cancers, and many small molecule inhibitors targeting its pathway components such as BRAF [11] and MEK [12] are approved or in clinical development.